Romiplostim N01 for Chemotherapy-induced Thrombocytopenia

Inclusion Criteria: * Age: 18 years or above, gender not restricted; * Patients who meet the diagnostic criteria for chemotherapy-related thrombocytopenia, and still ineffective after repeated treatment with rhTPO or IL-11 (subjects need to undergo regular rhTPO treatment for at least 14 days after radiotherapy and chemotherapy, with a dose of rhTPO 300u/kg/d or higher, and the platelet count remains less than 30×10\^9/L, defined as refractory CTIT); * Patients who have stopped chemotherapy and radiotherapy for more than 1 month; * Patients with platelet count at enrollment \< 30×10\^9/L; * Patients with platelet count remains \< 30×10\^9/L for more than 1 month; * Patients with expected survival period ≥ 6 months; * Patients with liver and kidney function \< 1.5× upper limit of normal value, physical examination qualified; * Patients with ECOG physical status score ≤ 2 points; * Patients with Cardiac function: New York Heart Association cardiac function classification is grade 2 or below; * Patients who is voluntary to sign the informed consent form; Exclusion Criteria: * Those with uncontrollable primary diseases of important organs, such as extensive metastasis of malignant tumors, liver failure, heart failure, kidney failure and other diseases； * Patients with poor compliance; * Positive serology for HIV, hepatitis B virus (HBV), hepatitis C virus (HCV), and/or hepatitis D virus (HDV), Syphilis; Positive for Epstein-Barr Virus DNA, Cytomegalovirus DNA; * Accompanied by…